Literature DB >> 3134309

Correlation between urokinase-type plasminogen activator production and the metastasizing ability of two murine mammary adenocarcinomas.

S Pereyra-Alfonso1, A Haedo, E Bal de Kier Joffé.   

Abstract

Plasminogen activator (PA) activity was studied in a transplantable murine mammary adenocarcinoma (M3), moderately metastatic to lungs, and in a highly metastatic variant tumor (MM3) to establish whether a correlation existed between this enzyme and the tumors' metastasizing abilities. The cell-associated and secreted PA activities from primary cultures of both tumors, as well as from solid tumor homogenates, were quantitated by means of a fibrinolytic assay. Immunoneutralization and zymographic assays were done to identify the PA present in both tumors. In culture, the highly metastasizing MM3 cells produced (secreted plus cell-associated activator) 3.3-fold higher PA levels than the M3 cells. This difference was mainly attributed to the enhanced secreting ability of MM3, as these tumor cells secreted 102 times their cell-associated PA activity within 24 hr, while M3 cells secreted only 11 times this activity during the same period. PA activity was also significantly higher in MM3 than in M3 tumor homogenates. Acid-labile inhibitors and non-specific proteases were not detected. In both tumors, PA was characterized as urokinase-type, with a molecular weight of approximately 48 kDa. These results suggest that, in this model, PA plays a role in metastasis formation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134309     DOI: 10.1002/ijc.2910420112

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  Hormonal regulation of plasminogen activator and peroxidase activities in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors and the rat uterus.

Authors:  K Inada; J Yamashita; T Yoshimura; S Matsuo; Y Nakashima; S Yamashita; A Misumi; M Ogawa
Journal:  Jpn J Surg       Date:  1991-03

2.  Developmental pattern of plasminogen activator activity in chick brain hemispheres.

Authors:  G Scicolone; S Pereyra-Alfonso; J L Ferrán; V Flores
Journal:  Neurochem Res       Date:  1998-09       Impact factor: 3.996

3.  Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model.

Authors:  D F Alonso; E F Farías; V Ladeda; L Davel; L Puricelli; E Bal de Kier Joffé
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

4.  Current Triton X-100 treatments do not allow a complete plasminogen activator extraction from developing nervous tissue.

Authors:  S Pereyra-Alfonso; G Scicolone; S Fiszer de Plazas; J P Saavedra; V Flores
Journal:  Neurochem Res       Date:  1995-02       Impact factor: 3.996

5.  Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells.

Authors:  E Bal de Kier Joffé; D F Alonso; L Puricelli
Journal:  Clin Exp Metastasis       Date:  1991 Jan-Feb       Impact factor: 5.150

6.  Urokinase-type plasminogen activator activity increases during the growth of two murine mammary adenocarcinomas with different metastasizing abilities.

Authors:  S Pereyra-Alfonso; G R Solarz; E Bal de Kier Joffé
Journal:  Clin Exp Metastasis       Date:  1992-11       Impact factor: 5.150

7.  Separation, purification and N-terminal sequence analysis of a novel leupeptin-sensitive serine endopeptidase present in chemically induced rat mammary tumour.

Authors:  I Eto; C J Grubbs
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.